awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q42392542-CA217EAA-898C-46E2-AC51-44975B0B7CDD
Q42392542-CA217EAA-898C-46E2-AC51-44975B0B7CDD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42392542-CA217EAA-898C-46E2-AC51-44975B0B7CDD
Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.
P2860
Q42392542-CA217EAA-898C-46E2-AC51-44975B0B7CDD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42392542-CA217EAA-898C-46E2-AC51-44975B0B7CDD
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
657b9352f248852c8dacc049a7e49bf9909a0a61
P2860
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.